🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jiang Liu

Center for Drug Evaluation and Research

ORCID: 0000-0002-5755-3904
Biochemistry, Genetics and Molecular BiologyMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations”.

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3713
N/A
1.7DataRank · unranked
58 citations

Erin Larkins, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Stephanie Aungst, Emily Wearne +13 more

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2072
N/A
1.7DataRank · unranked
42 citations

Liza Stapleford, Nicole Drezner, Anup Amatya, Pallavi S. Mishra‐Kalyani, Yuan Li Shen +22 more

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2036
N/A
1.6DataRank · unranked
60 citations

Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra‐Kalyani +12 more

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1270
N/A
1.2DataRank · unranked
46 citations

Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang +14 more

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0896
N/A
0DataRank · unranked
4 citations

Kamar Godder, Jingyan Wang, Justin S. Collazo, Robyn Konicki, Moran Choe +15 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1918
N/A
0DataRank · unranked
3 citations

Gabriela Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A. Davidson, Jiang Liu +4 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0098
N/A
0DataRank · unranked
1 citations

Cong Chen, Jin Y. Jin, Scott Van Wart, Sarah K. Martin, Brad A. Davidson +4 more

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0873
N/A
0DataRank · unranked
48 citations

Amy Barone, Somak Chatterjee, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Emasenyie Isikwei +14 more

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2196
N/A
0DataRank · unranked
10 citations

Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke, Haiyan Chen, Jonathon Vallejo +12 more

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1005
N/A
0DataRank · unranked
5 citations

Dianne Pulte, Xin Wang, Jonathon Vallejo, Ritu Chadda, Nan Zheng +10 more